Comparative effectiveness of methylprednisolone and zero-balance ultrafiltration on inflammatory response after pediatric cardiopulmonary bypass.

Abstract

Studies have demonstrated that systemic inflammatory response syndrome (SIRS) remains one of the major causes of cardiopulmonary bypass (CPB)-associated organ injury during pediatric cardiac surgery. The purpose of this investigation was to compare the effectiveness of methylprednisolone (MP) and zero-balance ultrafiltration (ZBUF) on SIRS during pediatric CPB. Thirty infants undergoing open-heart surgeries were randomized to receive either MP in the priming solution (group M, n = 15) or ZBUF during CPB (group Z, n = 15). All the patients survived. Plasma levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-10 (IL-10) were measured before CPB (T1), 5 min after the start of CPB (T2), at the termination of CPB (T3), the fourth hour (T4), and the eighth hour (T5) postoperatively. The results showed that the plasma concentrations of TNF-alpha in the Z group were significantly less than those in the M group at T4 and T5 (P < 0.05), and the plasma concentrations of IL-6 were significantly less than those in the M group at T4 (P < 0.05); the plasma concentrations of IL-8 in the Z group were significantly less than those in the M group at T5 (P < 0.05). There was no difference between two groups on the plasma concentrations of IL-10. The duration of postoperative mechanical ventilation was (9.6 +/- 0.8 h) in the M group and (7.8 +/- 0.4 h) in the Z group (P < 0.05). This study showed that application of ZBUF is more effective to decrease the level of inflammatory mediators including TNF-alpha, IL-6, and IL-8 than administration of MP after pediatric CPB.

• Authors: Jinping Liu, Bingyang Ji, Cun Long, Chunhua Li, Zhengyi Feng
• Journal: Artificial organs (Artif Organs) Vol. 31 Issue 7 Pg. 571-5 (Jul 2007) ISSN: 0160-564X [Print] United States
• PMID: 17584482 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• Interleukins
• Tumor Necrosis Factor-alpha
• Methylprednisolone

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Cardiopulmonary Bypass (adverse effects)
• Heart Defects, Congenital (surgery)
• Hemofiltration
• Humans
• Infant
• Interleukins (blood)
• Methylprednisolone (therapeutic use)
• Systemic Inflammatory Response Syndrome (blood, etiology, prevention & control)
• Tumor Necrosis Factor-alpha (blood)